Engine Biosciences Announces $43 Million Series A Round to Decipher Genetic Codes for New Medicines Through Machine Learning and Next-Generation Combinatorial Genetics
Important Findings from Pioneering Platform Advancing Drug Discovery and Development to Impact Treatments for Multiple Cancers
MAY 26, 2021 – SINGAPORE & SAN CARLOS, Calif.–(BUSINESS WIRE)–Engine Biosciences (“Engine”) today announced the successful completion of an oversubscribed $43 million Series A funding round. Engine identifies errors in the complex genetic codes of diseases, fixing them with precise therapeutic solutions. This round was led by Polaris Partners and also included new investors Invus and one of the world’s premier institutional investors, based in Singapore. Existing investors also participated in the Series A, which included 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper, and Nest.Bio. Amy Schulman, Managing Partner at Polaris Partners, has joined the Engine Biosciences Board of Directors. Engine has now raised $53 million to date, including $10 million in a 2018 seed round.
Located in Singapore and Silicon Valley, Engine has been operating at the intersection of data science, machine learning, high-throughput biology experimentation, combinatorial genetics, chemistry, and drug discovery. Engine’s technologies enable researchers and drug developers to uncover the gene interactions and biological networks underlying diseases orders-of-magnitude faster and more cost-effectively than conventional methods. Additionally, the company generates important insights for precision medicine applications.
“Many breakthrough tools to edit, program, and modulate biology have emerged and matured in recent years. The fundamental question continues to be whether we know the disease-driving errors in the genetic code of biology to direct these tools, including therapeutics,” said Jeffrey Lu, Engine Biosciences’ Co-Founder and CEO. “We are honored that this preeminent group of life science and technology investors has recognized the progress our team has made and is supporting our mission to unleash new medicines by deciphering biology.”
Engine has already been progressing its novel biology findings into drug discovery programs and proprietary small molecule inhibitors. It will utilize the new funds to expand its portfolio of precision oncology therapeutics, prepare for its first clinical programs, and scale its proprietary technology platform.
“The past year has reinforced the importance of rapid innovation and adaptation,” said Polaris Partners’ Amy Schulman. “Engine’s distinct combination of biology, technology, and drug discovery, as well as its global perspective, may well enable the company to be particularly capable of realizing the promise of artificial intelligence in drug discovery and tackling a wide variety of diseases. We are excited to be part of this next step with the team.”
Initial Disease Targets
Engine has performed several large-scale computational and experimental cycles with respect to genetic interactions and their relevance to multiple cancers, yielding new and subsequently validated discoveries. Engine’s growing and advancing pipeline of targeted therapies for genetically-defined patient populations has shown promise in treating liver, ovarian, colorectal, and breast cancers, representing major areas of unmet medical need and, in total, approximately 2.5 million deaths every year.
Through collaborations, Engine has also demonstrated its platform’s applicability in other disease areas and will continue to enable new therapeutics for more patients.
“We believe Engine’s AI-enabled technology platform has the potential to discover new biology targets and disease-causing links amongst known targets,” said Leon Chen, CEO and Founding Partner of 6 Dimensions Capital. “Considering the field’s tremendous needs for the right drug targets for the right patients and Engine’s unique capabilities in finding those, we continue to be excited by Engine’s potential to power new medicines.”
How It Works: NetMAPPR and CombiGEM
Two scientific innovations lie at the heart of Engine Biosciences: NetMAPPR and CombiGEM. NetMAPPR is Engine’s searchable biology platform, revealing gene combinations and drug targets integral to diseases. Employing combinatorial CRISPR, CombiGEM enables experimental confirmation of how genes and gene combinations relate to disease in supercharged fashion.
Engine has engineered NetMAPPR to operate in predict-test-learn cycles and scale for many research and drug discovery programs. Advanced computational tools leverage large patient and disease datasets and analyze the vast universe of millions-to-billions of gene interactions, making predictions on the most critical biologies for medicines. Engine uses its patented CombiGEM technology to test hundreds of thousands of gene interactions experimentally in diseased cells, thus breaking through bottlenecks in validation and data generation. The resulting data from well-controlled experiments improves Engine’s machine learning algorithms, while high-ranking genes are prioritized for drug discovery and development.
Compared to conventional approaches that are challenged by human limitations and less efficient and less precise experimental systems and hence cover tiny slices of biology, NetMAPPR searches much wider expanses of the complex architecture of biology at greater speeds, unleashing more new therapeutic opportunities.
About Engine Biosciences
Engine Biosciences is a venture-backed Singapore- and Silicon Valley-based company deciphering complex biology to unleash many impactful medicines. Our proprietary NetMAPPR platform integrates data science and machine learning, high-throughput biological experiments using our patented CombiGEM combinatorial genetics system, computational and wet lab chemistry, and drug discovery. We systematically analyze biological networks comprising millions-to-billions of gene interactions at greater speed and scale than conventionally possible, yielding promising drug targets for specific patient populations. Led by drug discovery and technology industry veterans and scientific pioneers, we are developing our growing pipeline of precision oncology therapeutics and working with partners to expand our impact. For more information, please visit www.enginebio.com
For U.S. office:
Element Public Relations
For Singapore office:
+65 8130 5694